Progress on ocular siRNA gene-silencing therapy and drug delivery systems

被引：36

作者：

Jiang, Jinjin ^{[1
,2
]}

Zhang, Xinru ^{[1
,2
]}

Tang, Yue ^{[1
,2
]}

Li, Shuhan ^{[2
]}

Chen, Jing ^{[2
]}

机构：

[1] Guizhou Med Univ, State Key Lab Funct & Applicat Med Plants, 1 DongQing Rd, Guiyang 550014, Peoples R China

[2] China Pharmaceut Univ, Dept Pharm, 639 Longmian Ave, Nanjing 211198, Peoples R China

来源：

FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2021年 / 35卷 / 01期

关键词：

age-related macular degeneration; glaucoma; RNA interference technology; siRNA drugs; non-viral vectors; ENDOTHELIAL GROWTH-FACTOR; BETA-ADRENERGIC RECEPTORS; VEGF SIRNA; POSTERIOR SEGMENT; POLYETHYLENIMINE NANOPARTICLES; INTRAVITREAL INJECTION; MACULAR DEGENERATION; NONVIRAL VECTORS; RNA INTERFERENCE; CLINICAL-TRIAL;

D O I：

10.1111/fcp.12561

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Age-related macular degeneration (AMD) and glaucoma are global ocular diseases with high blindness rate. RNA interference (RNAi) is being increasingly used in the treatment of these disorders with siRNA drugs, bevasiranib, AGN211745 and PF-04523655 for AMD, and SYL040012 and QPI-1007 for glaucoma. Administration routes and vectors of gene drugs affect their therapeutic effect. Compared with the non-viral vectors, viral vectors have limited payload capacity and potential immunogenicity. This review summarizes the progress of the ocular siRNA gene-silencing therapy by focusing on siRNA drugs for AMD and glaucoma already used in clinical research, the main routes of drug delivery and the non-viral vectors for siRNA drugs.

引用

页码：4 / 24

页数：21

共 50 条

[31] Nanotechnology approach for drug addiction therapy: Gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons
Bonoiu, Adela C.
Mahajan, Supriya D.
Ding, Hong
Roy, Indrajit
Yong, Ken-Tye
Kumar, Rajiv
Hu, Rui
Bergey, Earl J.
Schwartz, Stanley A.
Prasad, Paras N.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (14) : 5546 - 5550
[32] Progress in transdermal drug delivery systems for cancer therapy
Jiang, Tianyue
Xu, Guo
Chen, Guojun
Zheng, Yu
He, Bingfang
Gu, Zhen
NANO RESEARCH, 2020, 13 (07) : 1810 - 1824
[33] Advances in lipid-lowering therapy through gene-silencing technologies
Børge G. Nordestgaard
Stephen J. Nicholls
Anne Langsted
Kausik K. Ray
Anne Tybjærg-Hansen
Nature Reviews Cardiology, 2018, 15 : 261 - 272
[34] siRNA for gene silencing: a route to drug target discovery
Jones, SW
de Souza, PM
Lindsay, MA
CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (05) : 522 - 527
[35] Advances in lipid-lowering therapy through gene-silencing technologies
Nordestgaard, Borge G.
Nicholls, Stephen J.
Langsted, Anne
Ray, Kausik K.
Tybjoerg-Hansen, Anne
NATURE REVIEWS CARDIOLOGY, 2018, 15 (05) : 261 - 272
[36] Palmitic Acid-Conjugated 21-Nucleotide siRNA Enhances Gene-Silencing Activity
Kubo, Takanori
Yanagihara, Kazuyoshi
Takei, Yoshifumi
Mihara, Keichiro
Morita, Yasuhiro
Seyama, Toshio
MOLECULAR PHARMACEUTICS, 2011, 8 (06) : 2193 - 2203
[37] Sustained release ocular drug delivery systems for glaucoma therapy
Al-Qaysi, Zinah K.
Beadham, Ian G.
Schwikkard, Sianne L.
Bear, Joseph C.
Al-Kinani, Ali A.
Alany, Raid G.
EXPERT OPINION ON DRUG DELIVERY, 2023, 20 (07) : 905 - 919
[38] Smart contact lens systems for ocular drug delivery and therapy
Kim, Tae Yeon
Lee, Geon-Hui
Mun, Jonghwan
Cheong, Sunah
Choi, Inhoo
Kim, Hyemin
Hahn, Sei Kwang
ADVANCED DRUG DELIVERY REVIEWS, 2023, 196
[39] In-vivo gene silencing using topical delivery of siRNA
Thanik, Vishal
Greives, Matthew
Seiser, Natalie
Lerman, Oren
Hazen, Alexes
Levine, Jamie
Saadeh, Pierre
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2006, 203 (03) : S55 - S56
[40] Delivery of siRNA using cationic rosette nanotubes for gene silencing
Ho, Uyen
El-Bakkari, Mounir
Alshamsan, Aws
Cho, Jae-Young
Yamazaki, Takeshi
Hemraz, Usha D.
Fenniri, Hicham
BIOMATERIALS SCIENCE, 2023, 11 (21) : 7169 - 7178

← 1 2 3 4 5 →